Stroke
9 videos · updated daily
5:50 NOAH-AFNET 6: AF Burden and Anticoagulation
Prof Ulrich Schotten of Maastricht University discusses NOAH-AFNET 6 analyses presented at HRS 2026 on how atrial fibrillation burden in patients with device-detected atrial high-rate episodes relates to outcomes and to anticoagulation.
Walter Koroshetz on the State of Epilepsy Research
Former NINDS Director Dr. Walter Koroshetz discusses the state of epilepsy research, federal research funding, and how government, academia, industry and nonprofits do and don't collaborate, on CURE Epilepsy's Seizing Life podcast.
7:15 DOAC Monotherapy in AF With Stable Coronary Disease
Aditi Ujjawal, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School discusses her Mayo Clinic Proceedings analysis of six trials and 5,405 patients comparing anticoagulants with and without antiplatelets in AF with stable coronary disease.
2:28 PREMIUM Trial: Aspirin-Free Therapy After PCI in STEMI
Dr Gaku Nakazawa of Kindai University discusses the randomised Phase 4 PREMIUM trial of prasugrel monotherapy versus 12-month dual antiplatelet therapy after primary PCI for STEMI, recorded at ESC Congress for Radcliffe Cardiology.
8:48 OCEANIC-AF: Asundexian vs Apixaban in Atrial Fibrillation
Manesh Patel of Duke University Health System, principal investigator, discusses ESC 2024 data from the phase 3 OCEANIC-AF trial of asundexian versus apixaban in atrial fibrillation, which was halted early for lack of efficacy, for Radcliffe Cardiology.
40:40 How to Design an Adaptive Platform Trial
Ben Saville, PhD, president and lead statistical scientist of Adaptix Trials, explains how to design an adaptive platform trial, at the 2024 Adaptive Platform Trials Scientific Meeting in Toronto.
59:17 Detecting Site Fraud with Central Statistical Monitoring
IDDI presents a study in which CluePoints' central statistical monitoring, applied to the completed ESPS2 stroke prevention trial, ranked second of all sites the one whose patients had never received the protocol medications.
2:06 Defining Clinical Endpoints for Neurointervention Trials
Alexandra J. Lansky summarises a PCR-EAPCI Textbook chapter on consensus definitions and assessment of neurological endpoints for clinical trials in neurointervention, for PCR.
39:06 Vascular Phenotyping in Clinical Trial Design
Cardiex presents how vascular phenotyping, including arterial stiffness and endothelial function measures captured by digital health technologies, can be built into clinical trial design as biomarkers of therapeutic effect.